PT  - JOURNAL ARTICLE
AU  - Alexandr Klistorner
AU  - Michael Barnett
TI  - Remyelination Trials
AID  - 10.1212/NXI.0000000000001066
DP  - 2021 Nov 01
TA  - Neurology - Neuroimmunology Neuroinflammation
PG  - e1066
VI  - 8
IP  - 6
4099  - http://nn.neurology.org/content/8/6/e1066.short
4100  - http://nn.neurology.org/content/8/6/e1066.full
SO  - Neurol Neuroimmunol Neuroinflamm2021 Nov 01; 8
AB  - Neuroaxonal loss is believed to underpin the progressive disability that characterizes multiple sclerosis (MS). While focal inflammatory demyelination is a principal cause of acute axonal transection and subsequent axonal degeneration, the gradual attrition of permanently demyelinated axons may also contribute to tissue damage, particularly in the progressive phase of the disease. Therefore, remyelination is considered a putative neuroprotective strategy. In this article, we review the potential pitfalls of remyelination trials, provide a framework for their appropriate design and temper the expectations, at times unrealistic, of researchers, regulators and the pharmaceutical industry.DMT=disease-modifying therapy; FIDID=Feline Irradiated Diet-Induced Demyelination; MS=multiple sclerosis; PMD=Pelizaeus Merzbacher Disease